Form 4: CEO Edward Pershing Boosts Stake in Provectus Bio

Provectus Biopharmaceuticals CEO Edward Pershing acquired 34,940 shares of Series D-1 Convertible Preferred Stock in a private transaction, convertible into 349,400 common shares.

Summary

• Edward Pershing, CEO and Director of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT), acquired 34,940 shares of Series D-1 Convertible Preferred Stock.
• The acquisition occurred in a private transaction on February 9, 2026.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share.
• This acquisition represents an equivalent of 349,400 shares of common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless converted earlier.
• Following this transaction, Edward Pershing beneficially owns 2,613,807 derivative securities (common stock equivalent).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, as the CEO's significant personal investment through preferred stock conversion demonstrates high conviction in the company's value and future.

Positives

• The CEO's acquisition of a significant number of convertible preferred shares signals strong confidence in the company's future prospects.
• Insider buying, especially by top management, often indicates a belief that the stock is undervalued or that positive developments are anticipated.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the automatic conversion date of the Series D-1 Convertible Preferred Stock.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by a CEO, are often interpreted by the market as a strong vote of confidence in the company's strategic direction and future performance, potentially signaling positive developments within the biotechnology sector.

Related Party Transactions

• Edward Pershing, the CEO and a Director, acquired shares of Series D-1 Convertible Preferred Stock directly from the issuer in a private transaction.

Stakeholder Impact

• Shareholders may view the CEO's increased stake as a positive indicator of future company performance and management alignment with shareholder interests.

Next Steps

• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on December 31, 2028, unless converted earlier.

Key Dates

Recommendation

The CEO's substantial acquisition of convertible preferred stock, equivalent to 349,400 common shares, is a powerful signal of confidence. This insider buying suggests management believes the company is undervalued or anticipates significant positive developments, making it an attractive entry point for investors.

Keywords

Provectus Biopharmaceuticals, PVCT, Edward Pershing, Insider Trading, Form 4, Preferred Stock, Convertible Securities, CEO, Director, Equity Acquisition